SUCAMPO Aktie

6,07 EUR -1,2858%

Zu Ihrem Onlinebroker

kaufen verkaufen

SUCAMPO Aktienkurs : 08:11 ( 15 Min. verzögert)
6,07 € Letzter Kurs	-1,29% Veränderung	6,14 € Vortag	6,07 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
6,07 - 6,07 Tag	6,35 - 1,95 52 Wochen	0 Tag	9 Ø 52 Wochen	6,03 515 Stücke	6,25 497 Stücke

SUCAMPO Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

25.05.

IBD Meds Appear Safe in Pregnancy

Mahadevan advises Centocor, Abbott, Elan Pharmaceuticals, UCB, and Sucampo Pharmaceuticals and receives grants and research support from Prometheus Laboratories, Takeda, and GlaxoSmithKline. Her co-authors also are supported by various...
25.05.

Gaithersburg drug-maker signs deal for European market

Sucampo Pharmaceuticals recently reported more positive data from a study of its treatment for opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. The Bethesda company announc…

23.05.

Sucampo presents positive results from Phase III OBD trial

Sucampo Pharmaceuticals has presented positive data from a Phase III trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD). In the study, which estimated Amitiza (lubipros…
22.05.

Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in ...

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of positive data from a Phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD…
20.05.

Sucampo Presents Preclinical Data Showing Protective Effect Of Cobiprostone

(RTTNews) - Sucampo Pharmaceuticals, Inc. (SCMP: News ) announced the presentation of preclinical data at Digestive Disease Week 2012, in San Diego that...